cefalotin
Approved
Dec 18, 1974
Cephalothin is a first generation, semisynthetic analogue of natural cephalosporin antibiotic. The in-vitro bactericidal action of Cephalothin results from inhibition of cell-wall synthesis. In general, Cephalothin has higher activity against Gram positive than Gram negative organisms. Cephalothin is primarily indicated in conditions like bone and joint infection, genitourinary tract infections, respiratory tract infections, soft tissue and skin infections and others. The severe or irreversible adverse effects of Cephalothin, which give rise to further complications, include nephrotoxicity, hemolytic anemia. Cephalothin produces potentially life-threatening effects, which include anaphylaxis, serum sickness syndrome. The symptomatic adverse reactions produced by Cephalothin are: rashes, urticaria, allergic reactions, thrombophlebitis, pain at injection site. Co-administration of diuretics, such as furanthril, ethacrynic acid and nephrotoxic antibiotics may increase the risk of renal damage. Reciprocal inactivation could be observed during in vitro mixing of Cephalothin with aminoglycosides. — NCATS
Clinical trial activity
4 trials · 4 clinical orgs · 8 marketing orgs
Earliest trial started Oct 31, 2008 (NCT03877289)
Timeline
Indications
Approved for
Mechanism of action
- Bacterial penicillin-binding proteinINHIBITOR
Bacterial penicillin-binding protein inhibitor
- D-alanyl-D-alanine carboxypeptidase DacB (dacB) ↗
- Peptidoglycan D,D-transpeptidase FtsI (ftsI) ↗
- Penicillin-binding protein 1A (mrcA) ↗
- Penicillin-binding protein 1B (mrcB) ↗
- D-alanyl-D-alanine carboxypeptidase DacA (dacA) ↗
- Peptidoglycan D,D-transpeptidase MrdA (mrdA) ↗
- D-alanyl-D-alanine carboxypeptidase DacC (dacC) ↗
Approval history
- approvedDec 18, 1974
Chemistry & pharmacology
SMILES
CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3cccs3)[C@H]2SC1- Mol. weight
- 396.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL617 ↗
- WikipediaCefalotin ↗
- NCATSR72LW146E6 ↗
- ChEMBLCHEMBL1632 ↗
Also known as
- 38253
- 38253
- 3-acetoxymethyl-7-(2-thienylacetamido)-3-cephem-4-carboxylic acid
- 3-acetoxymethyl-7-(2-thienylacetamido)-3-cephem-4-carboxylic acid
- 7-(2-thienylacetamido)cephalosporanic acid
- 7-(2-thienylacetamido)cephalosporanic acid
- 7-(2'-thienylacetamido)cephalosporanic acid
- 7-(2'-thienylacetamido)cephalosporanic acid
- 7-(thiophene-2-acetamido)cephalosporin
- 7-(thiophene-2-acetamido)cephalosporin
- averon
- averon
- cefalothin
- cefalothin
- cefalotin
- cefalotin
- cefalotin
- cefalotin
- cefalotin
- cefalotin
- cefalotina
- cefalotina
- cefalotine
- cefalotine
- cefalotin sodium
- cefalotin sodium
- cefalotin sodium
- cefalotin sodium
- cefalotin sodium
- cefalotin sodium
- cefalotinum
- cefalotinum
- cephalothin
- cephalothin
- cephalothin
- cephalothin
- cephalothin
- cephalothin
- cephalothin sodium
- cephalothin sodium
- cephalothin sodium
- cephalothin sodium
- cephalothin sodium salt
- cephalotin
- cephalotin
- cephalotin
- cet
- cet
- keflin
- keflin
- keflin
- seffin
- seffin
- synclotin
- synclotin
- toricelocin
- toricelocin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06430736 | Phase 2 | Jul 1, 2024 | University of Bern |
| NCT03671681 | N/A | Nov 30, 2018 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta |
| NCT03324854 | N/A | Jul 1, 2016 | Universidad Autonoma de San Luis Potosi |
| NCT03877289 | Phase 4 | Oct 31, 2008 | University of Calgary |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Universidad Autonoma de San Luis Potosi | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Bern | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Calgary | Academic/Hospital | 1 | 1 | 1 | 2008 |
Marketing (10)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Abbott | For profit | MKTG | — |
| Abraxis | For profit | MKTG | — |
| Baxalta | For profit | MKTG | Jan 31, 1984 |
| Baxter | For profit | MKTG | Jan 31, 1984 |
| Bristol-Myers | For profit | MKTG | — |
| Eli Lilly | For profit | NDA | — |
| Eli Lilly | For profit | SYN | Dec 18, 1974 |
| Eli Lilly | For profit | MKTG | Sep 10, 1985 |
| GlaxoSmithKline | For profit | MKTG | — |
| International Medication | For profit | MKTG | — |